ERBB2 and gastritis: Notably, previous reports have described severe gastritis and hypoalbuminemia as adverse effects of zolbetuximab in patients with HER2-negative, CLDN-positive advanced gastric cancer.18,19) In contrast, the present patient experienced an uneventful clinical course with no evidence of severe hypoalbuminemia or postoperative complications.